Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$10.15 USD
+0.01 (0.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $10.09 -0.06 (-0.59%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Arcutis Biotherapeutics, Inc. (ARQT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.29 | $26.00 | $11.00 | 80.37% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Arcutis Biotherapeutics, Inc. comes to $18.29. The forecasts range from a low of $11.00 to a high of $26.00. The average price target represents an increase of 80.37% from the last closing price of $10.14.
Analyst Price Targets (7 )
Broker Rating
Arcutis Biotherapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/30/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
7/24/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
2/28/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
2/27/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $18.29 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.40 |
ARQT FAQs
Arcutis Biotherapeutics, Inc. (ARQT) currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Arcutis Biotherapeutics, Inc. (ARQT) is $18.29. The current on short-term price targets is based on 3 reports.
The forecasts for Arcutis Biotherapeutics, Inc. (ARQT) range from a low of $11 to a high of $26. The average price target represents a increase of $80.20 from the last closing price of $10.15.
The current UPSIDE for Arcutis Biotherapeutics, Inc. (ARQT) is 80.20%
Based on short-term price targets offered by seven analysts, the average price target for Arcutis Biotherapeutics, Inc. comes to $18.29. The forecasts range from a low of $11.00 to a high of $26.00. The average price target represents an increase of 80.37% from the last closing price of $10.14.